In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a ...

In a report released today, Patrick B Donnelly from Citi maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a price ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for. Exact Sciences missed analysts’ revenue ...

Operator Good day, everyone, and welcome to the Exact Sciences fourth quarter 2024 earnings call. Today's call is being ...

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

MADISON, Wis. - Exact Sciences Corp. (NASDAQ:EXAS) reported better-than-expected fourth quarter results on Tuesday, but its shares fell 1.5% in after-hours trading as investors appeared to seek ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Wednesday reported a loss of $864.6 million in its fourth quarter. On a per-share basis, the Madison, Wisconsin-based ...

Good day, everyone, and welcome to the Exact Sciences Fourth Quarter 2024 Earnings Call. Today's call is being recorded. All lines have been placed on mute to prevent any background noise.